STUART, Fla., Oct. 18, 2023 /PRNewswire/ — Stuart Therapeutics, Inc. (“Stuart”) today announced that it has entered into a license agreement with Glaukos Corporation (“Glaukos”) under which it has granted Glaukos exclusive worldwide rights to develop and commercialize Stuart’s…